Basket | Login | Register

 
 
 
 

VIVIAD (coming soon)

Phase II trials

Study Information

Name of the study

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

Study sponsor

Vivoryon Therapeutics AG

Disease

Mild cognitive impairment and mild Alzheimer’s disease

Phase

Phase II

Information about the drug that will be tested in the studies

Name of the drug

PQ912

Where and when will the study be conducted?

European countries involved in the trial (active)

  • Denmark
  • Germany
  • The Netherlands

Information for your doctor

Clinicaltrials.gov identifier

NCT04498650

Link to full text

https://clinicaltrials.gov/ct2/show/NCT04498650

 

 
 

Last Updated: Wednesday 11 November 2020

 

 
 

Options